The present invention provides methods and compositions for treating hyperlipidemia and/or hypercholesterolemia comprising administering to the subject an effective amount of an MTP inhibitor to inhibit hyperlipidemia and/or hypercholesterolemia in said subject, wherein said administration comprises an escalating series of doses of the MTP inhibitor. In some embodiments the method comprises administering at least three step-wise, increasing dosages of the MTP inhibitor to the subject. In some embodiments, the method further comprises the administration of one or more other lipid modifying compounds.

The present invention concerns methods for treating and preventing renal/kidney disease, insulin resistance/diabetes, fatty liver disease, and/or endothelial dysfunction/cardiovascular disease using synthetic triterpenoids, optionally in combination with a second treatment or prophylaxis.

A method of preparing water-soluble lutein ester microcapsules includes: mixing marigold flower particles with an extracting solvent, refluxing at 65-85° C.; removing the extracting solvent to obtain a crude extract; washing the crude extract with a washing solvent; removing the washing solvent to obtain a crude lutein ester; adding an oil-phase antioxidant and a vegetable oil to the crude lutein ester, mixing and heating at 90-100° C. to obtain a lutein ester oil phase; adding a wall material, an emulsifier, a water-phase antioxidant, and a water-phase filler into water, and heating to obtain a water phase; adding the lutein ester oil phase to the water phase under a high-speed shearing, mixing evenly, and homogenizing to obtain a lutein ester emulsion; drying twice to obtain semi-finished lutein ester microcapsules; and solidifying to obtain the lutein ester microcapsules. Water-soluble lutein ester microcapsules prepared by the method are also disclosed.

The present disclosure relates to compositions and systems for improving tissue perfusion such that blood flow is increased, improving tissue healing time and reducing or eliminating tissue necrosis. In a preferred embodiment, the compositions comprise a phosphodiesterase inhibitor, a calcium channel blocker, a nitric oxide producer, and an α-adrenergic antagonist. Methods of making the compositions and using the compositions are also disclosed.

The present disclosure relates to compositions and systems for improving tissue perfusion such that blood flow is increased, improving tissue healing time and reducing or eliminating tissue necrosis. In a preferred embodiment, the compositions comprise a phosphodiesterase inhibitor, a calcium channel blocker, a nitric oxide producer, and an α-adrenergic antagonist. Methods of making the compositions and using the compositions are also disclosed.

This invention relates to a treatment of various eye conditions relating to eye enlargement. The conditions can be treated by inhibiting an upstream protein within the said biological pathway or by increasing the expression of a downstream receptor within the same pathway. Inhibition of the upstream protein, sterol regulatory element binding protein (SREBP), has been achieved using small molecule inhibitors or nucleic acid in viral vector and increased expression of the downstream protein, bone morphogenetic protein (BMP), has been achieved by nucleic acid in viral vector. The invention relates to the small molecule, nucleic acid and the viral vector as well as methods of treating the ocular diseases.

This invention relates to a treatment of various eye conditions relating to eye enlargement. The conditions can be treated by inhibiting an upstream protein within the said biological pathway or by increasing the expression of a downstream receptor within the same pathway. Inhibition of the upstream protein, sterol regulatory element binding protein (SREBP), has been achieved using small molecule inhibitors or nucleic acid in viral vector and increased expression of the downstream protein, bone morphogenetic protein (BMP), has been achieved by nucleic acid in viral vector. The invention relates to the small molecule, nucleic acid and the viral vector as well as methods of treating the ocular diseases.

This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.

This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.

This document provides methods and materials involved in killing HIV infected cells (e.g., CD4 T cells). For example, methods and materials for using one or more Bcl-2 inhibitors (e.g., ABT-199) alone or in combination with one or more agents capable of reactivating HIV (e.g., latency reversing agent) to kill HIV infected cells (e.g., CD4 T cells) are provided.